Human DCAF12L2 has no direct experimental evidence supporting its assembly with DDB1 or its function as a CRL4 substrate receptor. Its annotation as a CRL4 complex member derives entirely from phylogenetic inference (GO evidence code IBA—Inferred from Biological Aspect of Ancestor) transferred from its paralog DCAF12, with which it shares 63.5% sequence identity. While DCAF12 is among the best-characterized DCAFs—with cryo-EM structures, validated substrates, mutagenesis data, and defined degron specificity—none of this experimental apparatus has been replicated for DCAF12L2. The gap between the two paralogs is not merely quantitative but qualitative: DCAF12L2 lacks any published biochemical reconstitution, any direct DDB1 binding assay, any substrate validation, and any structural data whatsoever.
Low-confidence co-purification of DCAF12L2 with CUL4A and CUL4B has been detected in large-scale proteomics studies (Bennett et al. 2010; Huttlin et al. 2017), but critically, DDB1 itself has never been detected as a DCAF12L2 interaction partner in any published dataset—an unexpected absence if DCAF12L2 were a canonical DCAF, since DDB1 is the obligate bridge between substrate receptors and the CUL4 scaffold. Sequence analysis reveals that while the critical WD40-embedded R368 (WDXR motif) required for DDB1 binding is conserved in DCAF12L2 (as R378), the HLH-box motif that provides a second DDB1-binding surface shows key charge and polarity substitutions that could compromise binding.
Of four candidate substrates mentioned in literature or databases (MEKK4, WDR11, FAM91A1, MCMBP), none has been validated as a DCAF12L2 substrate by any direct assay, and only WDR11 possesses the C-terminal di-Glu degron motif that DCAF12 is known to recognize. Curating DCAF12L2 with CRL4 substrate receptor molecular function or degron specificity would be premature and represents a case where family-level inference is being overextended beyond what current experimental evidence can support.
The UniProt entry for DCAF12L2 (Q5VW00) carries an annotation score of just 2.0 out of 5.0 and contains zero functional experimental references. Its sole Gene Ontology annotation for CRL4 complex membership (GO:0080008, "Cul4-RING E3 ubiquitin ligase complex") is assigned with evidence code IBA (Inferred from Biological Aspect of Ancestor), generated by the GO_Central phylogenetic annotation pipeline. This annotation was propagated from DCAF12 (Q5T6F0), which carries the same GO term with evidence code IDA (Inferred from Direct Assay)—a qualitatively different level of support.
Interaction databases provide only marginal support for CRL4 association:
| Interactor | Source | Confidence | Notes |
|---|---|---|---|
| CUL4A | IntAct (PMID: 21145461) | intact-miscore 0.35 | High-throughput CRL network proteomics |
| CUL4B | IntAct (PMID: 28514442) | intact-miscore 0.35 | BioPlex 2.0 mass spectrometry |
| DDB1 | STRING | Experimental: 0.115; Database: 0.540 | Not detected in any co-purification |
| DDA1 | STRING | Experimental: 0.000; Database: 0.540 | Purely inferred from family classification |
The STRING association score for DDB1 is dominated by the "database" channel (0.540), which reflects family-level classification rather than experimental evidence. The experimental score (0.115) is negligible. This pattern—where the informatics signal is strong but the experimental signal is absent—is a hallmark of annotation transfer that has outrun the underlying data.
Raisch et al. (2023) systematically tested which WD40 proteins genuinely interact with DDB1 using both BioID proximity labeling and affinity purification–mass spectrometry. As they stated: "Using BioID and affinity purification-mass spectrometry approaches, we demonstrated that seven WD40 proteins can be considered DCAFs with a high confidence level" (PMID: 37689310). That only seven of approximately 60 bioinformatically predicted DCAFs passed this validation underscores that the "DCAF" designation is provisional for proteins that have not been individually tested—and DCAF12L2 was not among those validated.
Global pairwise alignment (EMBOSS Needle, BLOSUM62 matrix) between DCAF12 (453 aa) and DCAF12L2 (463 aa) reveals substantial but imperfect conservation:
| Region | Identity | Similarity |
|---|---|---|
| Full-length | 298/469 (63.5%) | 356/469 (75.9%) |
| WD40 core | ~68.2% | ~76.5% |
| C-terminal 19 residues | 100% | 100% |
| HLH-box (DDB1-binding) | Divergent at key positions | — |
The WDXR motif is a critical determinant of DDB1 binding for WD40-containing DCAFs, first characterized by Jin et al. (2006), who showed that "DCAFs interact with multiple surfaces on Ddb1, and the interaction of WD40-containing DCAFs with Ddb1 requires a conserved 'WDXR' motif" (PMID: 16949367). The arginine at position 368 in DCAF12, whose mutation abolishes DDB1 binding, is conserved as R378 in DCAF12L2. This conservation is necessary but not sufficient for DDB1 binding, because DCAFs employ a bipartite DDB1 interface.
The second binding surface involves the HLH-box motif (DCAF12 residues 45–57), which was crystallized bound to DDB1 in PDB 3I7P. Alignment of this region reveals functionally significant substitutions:
Position (DCAF12 numbering): 45 46 47 48 49 50 51 52 53 54 55 56 57
DCAF12: S L V Y Y L K N R E V R L
DCAF12L2: R L V H Y L K G R E V G A
^ ^ ^
N→G R→G L→A
The substitution of N52→G57 eliminates a polar side chain capable of hydrogen bonding with DDB1, while R56→G61 removes a positively charged residue, potentially disrupting an electrostatic contact. These are not conservative substitutions and could meaningfully weaken or abolish the HLH-box–DDB1 interaction even if the WDXR motif remains functional. The convergence of sequence divergence at the HLH-box with the absence of any DDB1 co-purification hit makes it plausible that DCAF12L2 has reduced or lost DDB1-binding capability.
Four proteins have been mentioned in various contexts as potential DCAF12L2 substrates or interactors: MEKK4 (MAP3K4), WDR11, FAM91A1, and MCMBP. None of these appears in IntAct, STRING, or BioPlex as a direct DCAF12L2 interactor. Their candidacy likely derives from computational prediction, unpublished proteomics, or curation discussions rather than published experimental validation.
We assessed whether their C-terminal sequences are compatible with the DCAF12 degron grammar—the C-terminal di-Glu motif established by structural and biochemical studies. Righetto et al. (2024) showed that "DCAF12 serves as the substrate recognition component within the Cullin4-RING E3 ligase (CRL4) complex, capable of identifying C-terminal double-glutamic acid degrons to promote the degradation of specific substrates through the ubiquitin proteasome system" (PMID: 38665159):
| Candidate | C-terminal 5 residues | Di-Glu motif? | Acidic residues (last 5) | Degron compatible? |
|---|---|---|---|---|
| MEKK4 (MAP3K4) | SLLSW | No | 0 | No |
| WDR11 | EPIEE | Yes | 3 (E, E, E) | Yes |
| FAM91A1 | NLHLQ | No | 0 | No |
| MCMBP | NGNEL | No | 1 (E) | No |
For comparison, validated DCAF12 substrates:
| Substrate | C-terminal motif | Reference |
|---|---|---|
| MAGEA3 | ...REGEE | PMID: 31267705 |
| MAGEA6 | ...REGEE | PMID: 31267705 |
| CCT5 | ...GESEE | PMID: 36715408 |
| MOV10 | ...Glu-Leu C-term | PMID: 34065512 |
Only WDR11 possesses a C-terminal sequence (EPIEE) resembling the validated di-Glu degron. Intriguingly, WDR11 is itself a receptor for acidic-cluster-containing cargo proteins in vesicle trafficking—as Deng et al. (2024) showed, "WDR11 directly and specifically recognizes a subset of acidic clusters, which we term super acidic clusters (SACs)" (PMID: 39013469). However, there is no published evidence that DCAF12L2 (or DCAF12) actually targets WDR11 for ubiquitination or degradation.
The MCMBP connection warrants special attention because of paralog confusion. CRL4^DCAF12L1^ (note: DCAF12L1, a different paralog) was recently shown to regulate MCMBP and MCM2-7 hexamer equilibrium (PMID: 41145411). This demonstrates that distinct DCAF12 family members have distinct biological roles—an activity experimentally demonstrated for DCAF12L1 should not be assumed for DCAF12L2 without independent validation.
To calibrate expectations for what "validated" means in this context, DCAF12 provides the benchmark:
DCAF12L2 has none of these evidence types. The contrast is stark: a protein can be named a "DCAF" and annotated as a CRL4 component while possessing zero functional evidence.
IntAct lists 29 unique interaction partners for DCAF12L2 (Q5VW00), predominantly from two large-scale studies: Schaffer et al. 2025 (PMID: 40205054) and Huttlin et al. 2017 (PMID: 28514442). The interaction set shows a striking enrichment for protein folding quality control machinery:
| Complex/Family | Interactors detected |
|---|---|
| TRiC/CCT chaperonin | CCT2, CCT3, CCT5, CCT7, CCT8 |
| Prefoldin/GimC | PFDN1, PFDN2, PFDN4, PFDN5, PFDN6, VBP1 |
| Phosducin-like chaperones | PDCL, PDCL3 |
| Mitochondrial protease | LONP1 |
| CoREST complex | RCOR1, RCOR2, RCOR3 |
| CRL4 scaffold | CUL4A, CUL4B |
| Known DCAF12 substrate | MAGEA6 |
This enrichment parallels DCAF12's validated role in non-degradative ubiquitination of TRiC/CCT subunits (PMID: 41047465). However, these are all high-throughput co-purification hits, not targeted validations. The presence of MAGEA6 (a validated DCAF12 substrate bearing the di-Glu degron) is notable but could reflect indirect association through shared complex members rather than direct substrate recognition. These data are suggestive enough to motivate follow-up experiments but insufficient for functional annotation.
The DCAF12 family in humans includes three paralogs: DCAF12, DCAF12L1, and DCAF12L2. Despite sharing a common WD40-repeat architecture and the "DCAF" designation, these paralogs appear to have functionally diverged:
DCAF12 family
|
+----------------+----------------+
| | |
DCAF12 DCAF12L1 DCAF12L2
| | |
CRL4 substrate CRL4 substrate Unknown function
receptor (IDA) receptor (IDA) (IBA annotation only)
| | |
Di-Glu degron MCMBP regulation No validated substrates
recognition (MCM2-7 assembly) No DDB1 binding detected
MAGEA3/6, CCT5, | HLH-box diverged
MOV10, TRiC/CCT PMID: 41145411
|
Multiple structures
(PDB: 8AJM, 8AJN,
8T9A, 3I7P)
Several lines of evidence converge to suggest that DCAF12L2's CRL4 function cannot simply be assumed from family membership:
Missing DDB1 interaction: The absence of DDB1 from any DCAF12L2 co-purification dataset is the single most significant piece of negative evidence. For a canonical DCAF, DDB1 binding is the defining interaction—it is the bridge that connects the substrate receptor to the CUL4 scaffold. DDB1 is abundant and readily detected in pulldowns of validated DCAFs.
HLH-box divergence: The bipartite DDB1-binding interface requires both the WDXR motif (conserved) and the HLH-box (divergent). Loss of either surface can abolish or weaken DDB1 binding. The N→G and R→G substitutions in the DCAF12L2 HLH-box remove hydrogen-bonding and electrostatic contacts respectively.
No validated substrates: Despite the existence of high-throughput screens that have identified substrates for dozens of other DCAFs (e.g., Koren et al. 2018, PMID: 29779948), no substrates have emerged for DCAF12L2.
Systematic DCAF validation excludes it: Raisch et al. (2023) specifically set out to validate which WD40 proteins are genuine DCAFs and confirmed only seven with high confidence—DCAF12L2 was not among them.
Retroposition origin: DCAF12L2 arose by retroposition from DCAF12 (PMID: 20889727) and has undergone "intronization" events in primate and rodent lineages. Retrogenes frequently acquire new functions, lose function, or become restricted to specific tissues.
If DCAF12L2 is not a canonical CRL4 substrate receptor, several possibilities emerge from the available data:
| PMID | Authors | Year | Key Contribution |
|---|---|---|---|
| 16949367 | Jin et al. | 2006 | WDXR motif for DDB1 binding; R368 mutagenesis in DCAF12 |
| 19966799 | Li et al. | 2010 | HLH-box motif structure (PDB 3I7P) |
| 20889727 | Szczesniak et al. | 2011 | DCAF12L2 as retrogene with primate-specific intronization |
| 21145461 | Bennett et al. | 2010 | CRL network proteomics (CUL4A–DCAF12L2 hit) |
| 28514442 | Huttlin et al. | 2017 | BioPlex 2.0 (CUL4B–DCAF12L2 hit) |
| 29779948 | Koren et al. | 2018 | C-end degron rules; DCAF12 as CRL4 adaptor for di-Glu degrons |
| 31267705 | Ravichandran et al. | 2019 | CRL4–DCAF12 degrades MAGE-A3/6 |
| 33961781 | Huttlin et al. | 2021 | BioPlex 3.0 interactome |
| 34065512 | Lidak et al. | 2021 | CRL4–DCAF12 controls MOV10 via C-terminal degron |
| 36715408 | Pla-Prats et al. | 2023 | Cryo-EM: CRL4–DCAF12–CCT5 di-Glu degron |
| 37689310 | Raisch et al. | 2023 | Systematic DCAF validation; only 7 of ~60 confirmed |
| 38665159 | Righetto et al. | 2024 | Cryo-EM: DDB1–DCAF12–MAGEA3 structural basis |
| 39013469 | Deng et al. | 2024 | WDR11–FAM91A1 recognizes acidic clusters |
| 40205054 | Schaffer et al. | 2025 | Multimodal cell maps (DCAF12L2 interactions) |
| 41047465 | Lu et al. | 2025 | DCAF12 non-degradative ubiquitination of TRiC/CCT |
| 41145411 | Yadav et al. | 2025 | CRL4–DCAF12L1 regulates MCMBP/MCM equilibrium |
| 41560323 | Review | 2025 | DCAF12–TRiC/CCT axis in metastatic proteostasis |
Supporting the inference gap: Raisch et al. (PMID: 37689310) is the single most important paper for understanding why DCAF12L2 should not be assumed to be a functional DCAF. By systematically testing DCAF candidates and validating only 7, they demonstrated that the "DCAF" label is far more promissory than definitive for untested members.
Establishing the degron benchmark: Pla-Prats & Schulman (PMID: 36715408) and Righetto et al. (PMID: 38665159) provide atomic-level understanding of how DCAF12 recognizes C-terminal di-Glu degrons, enabling us to assess candidate substrates. Three of four DCAF12L2 candidates fail this test.
Highlighting paralog confusion risk: Yadav et al. (PMID: 41145411) demonstrated that CRL4^DCAF12L1^—not DCAF12L2—regulates MCMBP. This illustrates how easily functional annotations can be misattributed across paralogs when names differ by a single character.
Absence of evidence ≠ evidence of absence: DCAF12L2 has simply not been studied in targeted experiments. It is possible that it does bind DDB1 and function as a CRL4 receptor, but no one has tested this with recombinant proteins, co-immunoprecipitation from endogenous sources, or proximity labeling focused specifically on DCAF12L2.
High-throughput proteomics sensitivity: The CUL4A/CUL4B interactions detected in Bennett et al. and BioPlex could be genuine but weak/transient, or they could reflect indirect associations through other complex members. The low intact-miscore (0.35) makes this ambiguous.
Expression-level considerations: DCAF12L2 may be expressed at low levels or in restricted tissues. It has appeared in cancer transcriptomics studies—as a prognostic marker for breast cancer (PMID: 37986376) and as a mutation hotspot gene in microsatellite-unstable colorectal cancers (PMID: 23684749)—but these are correlative associations rather than functional characterizations.
Retroposition origin: DCAF12L2 arose via retroposition from DCAF12 (PMID: 20889727), which means it originally lacked introns and regulatory elements. Its subsequent "intronization" events suggest ongoing evolutionary remodeling, but whether its protein product has retained, modified, or lost ancestral function is unknown.
Candidate substrate provenance: The source of the candidate substrate list (MEKK4, WDR11, FAM91A1, MCMBP) could not be traced to a primary publication demonstrating DCAF12L2-mediated degradation. It may derive from unpublished proteomics, a thesis, or a GO curation discussion.
Structural analysis limitations: Assessment of degron-binding pocket conservation is limited by the absence of a DCAF12L2 experimental structure. AlphaFold models could partially address this but have not been formally compared.
Direct DDB1 binding assay: Express recombinant DCAF12L2 (full-length and WD40 domain) and test binding to DDB1 by pulldown, surface plasmon resonance (SPR), or isothermal titration calorimetry (ITC). Compare wild-type with R378A mutant (WDXR motif). This single experiment would definitively resolve whether DCAF12L2 can engage DDB1.
BioID/TurboID proximity labeling: Express DCAF12L2-BirA* in HEK293T cells and perform streptavidin pulldown followed by mass spectrometry. If DDB1, CUL4A, and RBX1 are biotinylated, this confirms CRL4 proximity in living cells.
HLH-box chimera experiment: Replace the DCAF12L2 HLH-box (residues 50–62) with that of DCAF12 and test whether this restores DDB1 binding. This would determine whether the HLH-box divergence is functionally consequential.
GPS (Global Protein Stability) profiling: Co-express DCAF12L2 with the GPS reporter library to identify potential substrates in an unbiased manner—rather than assuming they must match DCAF12's degron grammar.
C-terminal peptide binding assay: Test whether DCAF12L2's WD40 domain binds di-Glu C-terminal peptides using fluorescence polarization or SPR. If binding is absent, this rules out shared degron specificity with DCAF12.
WDR11 degradation assay: Since WDR11 is the only candidate with a compatible C-terminal degron (EPIEE), test whether DCAF12L2 overexpression promotes WDR11 degradation and whether this is blocked by MLN4924 (neddylation inhibitor).
Tissue expression profiling: Determine where DCAF12L2 is expressed at protein level (not just mRNA) to guide cell line selection for functional studies.
Evolutionary analysis: Perform dN/dS analysis across mammals to determine whether DCAF12L2 is under purifying selection (suggesting conserved function) or relaxed constraint (suggesting functional drift or pseudogenization).
AlphaFold structural comparison: Compare AlphaFold-predicted structures of DCAF12 and DCAF12L2 docked onto DDB1 to computationally assess whether the HLH-box divergence is compatible with binding.
Report generated 2026-07-06. Based on systematic analysis of 36 publications, sequence alignments (EMBOSS Needle), interaction database queries (IntAct, STRING, BioPlex), and structural comparison with validated DCAF12.